Author: claimsbot

1. A rotating sleeve lock switch comprising:
a. a main body;
b. a button having an axis, wherein the button is mounted to the main body;
c. a first engagement member formed on the button;
d. a sleeve lock rotably mounted to the main body, wherein the sleeve lock has a sleeve lock internal surface, wherein the sleeve lock internal surface has a second engagement member that is configured to receive the first engagement member when the sleeve lock is in an unlocked position; and
e. a button stop shoulder formed on the sleeve lock, wherein the button stop shoulder engages the first engagement member to prevent pressing of the button when the sleeve lock is in a locked position, wherein the sleeve lock is configured to transition between the locked position and the unlocked position by rotation of the sleeve lock.
2. The rotating sleeve lock switch of claim 1, further comprising: a button position spring having a spring arm terminating in a spring arm tip, wherein the sleeve lock internal surface includes a position slot formed in a parallel direction to the axis, wherein the position slot engages and disengages the spring arm tip as the sleeve lock rotates around the main body and around the button.
3. The rotating sleeve lock switch of claim 1, further comprising: a contact mounted to the button, wherein the contact has a contact retaining surface that engages an inside surface of the main body to retain the button to the main body.
4. The rotating sleeve lock switch of claim 1, further comprising: a sleeve lock stop shoulder formed on the main body, and further comprising a sleeve retainer having a sleeve retainer ring flange that extends from the sleeve retainer, wherein the sleeve retainer is mounted to the main body at a sleeve retainer thread, wherein the sleeve lock is retained in a rotable state between the sleeve lock stop shoulder and the sleeve retainer ring flange.
5. The rotating sleeve lock switch of claim 1, further comprising: a button helical spring mounted in a button helical spring slot formed on the main body, wherein the button helical spring biases the button into a neutral position.
6. The rotating sleeve lock switch of claim 1, further comprising: a sleeve lock stop shoulder formed on the main body, and further comprising a sleeve retainer having a sleeve retainer ring flange that extends from the sleeve retainer, wherein the sleeve retainer is mounted to the main body at a sleeve retainer thread, wherein the sleeve lock is retained in a rotable state between the sleeve lock stop shoulder and the sleeve retainer ring flange; and a button helical spring mounted in a button helical spring slot formed on the main body, wherein the button helical spring biases the button into a neutral position.
7. The rotating sleeve lock switch of claim 1, wherein the first engagement member is a protrusion, and wherein the second engagement member is an indentation.
8. The rotating sleeve lock switch of claim 7, further comprising: a button position spring having a spring arm terminating in a spring arm tip, wherein the sleeve lock internal surface includes a position slot formed in a parallel direction to the axis, wherein the position slot engages and disengages the spring arm tip as the sleeve lock rotates around the main body and around the button.
9. The rotating sleeve lock switch of claim 7, further comprising: a contact mounted to the button, wherein the contact has a contact retaining surface that engages an inside surface of the main body to retain the button to the main body.
10. The rotating sleeve lock switch of claim 7, further comprising: a sleeve lock stop shoulder formed on the main body, and further comprising a sleeve retainer having a sleeve retainer ring flange that extends from the sleeve retainer, wherein the sleeve retainer is mounted to the main body at a sleeve retainer thread, wherein the sleeve lock is retained in a rotable state between the sleeve lock stop shoulder and the sleeve retainer ring flange.
11. The rotating sleeve lock switch of claim 7, further comprising: a button helical spring mounted in a button helical spring slot formed on the main body, wherein the button helical spring biases the button into a neutral position.
12. The rotating sleeve lock switch of claim 7, further comprising: a sleeve lock stop shoulder formed on the main body, and further comprising a sleeve retainer having a sleeve retainer ring flange that extends from the sleeve retainer, wherein the sleeve retainer is mounted to the main body at a sleeve retainer thread, wherein the sleeve lock is retained in a rotable state between the sleeve lock stop shoulder and the sleeve retainer ring flange; and a button helical spring mounted in a button helical spring slot formed on the main body, wherein the button helical spring biases the button into a neutral position.
13. The rotating sleeve lock switch of claim 7, wherein the button includes a button spacer portion and button adapter portion as an integral part of the button.
14. The rotating sleeve lock switch of claim 13, further comprising: a sleeve lock stop shoulder formed on the main body, and further comprising a sleeve retainer having a sleeve retainer ring flange that extends from the sleeve retainer, wherein the sleeve retainer is mounted to the main body at a sleeve retainer thread, wherein the sleeve lock is retained in a rotable state between the sleeve lock stop shoulder and the sleeve retainer ring flange.
15. The rotating sleeve lock switch of claim 13, further comprising: a sleeve lock stop shoulder formed on the main body, and further comprising a sleeve retainer having a sleeve retainer ring flange that extends from the sleeve retainer, wherein the sleeve retainer is mounted to the main body at a sleeve retainer thread, wherein the sleeve lock is retained in a rotable state between the sleeve lock stop shoulder and the sleeve retainer ring flange; and a button helical spring mounted in a button helical spring slot formed on the main body, wherein the button helical spring biases the button into a neutral position.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

What is claimed is:

1. A composition for local administration of an anti-tumor chemotherapeutic to a patient having a tumor, the composition comprising;
a plurality of microspheres incorporating the anti-tumor chemotherapeutic surrounded by a suspending solution.
2. The composition of claim 1, wherein the anti-tumor chemotherapeutic is in a formulation comprising a mixture of the anti-tumor chemotherapeutic and a plasma protein in an amount effective to solubilize the anti-tumor chemotherapeutic.
3. The composition of claim 2, wherein the plasma protein is selected from the group consisting of human serum albumin and -immunoglobulin.
4. The composition of claim 2, wherein the longest diameter of the microspheres is less than about 20 microns.
5. The composition of claim 2, wherein the microspheres are microcapsules.
6. The composition of claim 2, wherein the anti-tumor chemotherapeutic is contained within the microsphere.
7. The composition of claim 2, wherein the anti-tumor chemotherapeutic is attached to the microsphere.
8. The composition of claim 2, wherein the microspheres comprises a biodegradable polymer.
9. The composition of claim 8, wherein the biodegradable polymer is selected from the group consisting of polyacetic acid, polyglycolic acid and a co-polymer of polyglycolic and polyacetic acid.
10. The composition of claim 2, wherein the microspheres comprise a non-biodegradable polymer.
11. The composition of claim 13 wherein, the non-biodegradable polymer is an ethylene-vinyl acetate copolymer.
12. The composition of claim 2, wherein degradation of the microspheres releases the anti-tumor chemotherapeutic from the microspheres in a therapeutically effective amount.
13. The composition of claim 12, wherein up to about 50% of the anti-tumor chemotherapeutic is released from the microspheres within about 24 hours after administration of the microspheres to the patient.
14. The composition of claim 12, wherein between about 15 to about 25% of the anti-tumor chemotherapeutic is released from the microspheres within about 24 hours after administration of the microspheres to the patient.
15. The composition of claim 2, wherein the anti-tumor chemotherapeutic is released from the microsphere by diffusion.
16. The composition of claim 15, wherein the anti-tumor chemotherapeutic is released in a therapeutically effective amount over a period of time from about 1 week to about six months after administration to the patient.
17. The composition of claim 15, wherein the anti-tumor chemotherapeutic is released in a therapeutically effective amount over a period of time from about 3 weeks to about 2 months after administration to the patient.
18. The composition of claim 2, wherein the anti-tumor chemotherapeutic is an apoptosis inducing chemotherapeutic.
19. The composition of claim 18, wherein the apoptosis inducing chemotherapeutic is selected from the group consisting of cisplatin, adriamycin, butyric acid, cyclophosphamide, etoposide, amsacrine, genistein, and mitoguazone.
20. The composition of claim 18, wherein the anti-tumor chemotherapeutic is paclitaxel.
21. The composition of claim 20, wherein the paclitaxel is at a concentration from about 0.1 to about 10 mgmL.
22. The composition of claim 20, wherein the paclitaxel is at a concentration from about 0.5 to about 5 mgmL.
23. The composition of claim 2, wherein the suspending solution also includes an apoptosis inducing chemotherapeutic.
24. The composition of claim 23, wherein the apoptosis inducing chemotherapeutic is paclitaxel.
25. The composition of claim 24, wherein the paclitaxel in both the microspheres and in the solution is about 70 to about 280 mg.
26. The composition of claim 24, wherein the paclitaxel in both the microspheres and in the solution is at a concentration of about 135 mgm2 to about 175 mgm2.
27. The composition of claim 23, wherein between about 10% to about 90% of the paclitaxel is present in the microspheres.
28. The composition of claim 23, wherein between about 60% to about 90% of the paclitaxel is present in the microspheres.
29. The composition of claim 23, wherein between about 80% to about 90% of the paclitaxel is present in the microspheres.
30. The composition of claim 2, further comprising a second anti-tumor chemotherapeutic in the suspending solution.
31. The composition of claim 30, wherein the second anti-tumor chemotherapeutic is an apoptosis inducing chemotherapeutic.
32. The composition of claim 30, wherein the second anti-tumor chemotherapeutic is selected from the group consisting of paclitaxel, cisplatin, adriamycin, butyric acid, cyclophosphamide, etoposide, amsacrine, genistein, and mitoguazone.
33. A method for local administration of an anti-tumor chemotherapeutic to a tumor, comprising the steps of:
delivering a chemotherapeutic reservoir to the tumor; and,
releasing the chemotherapeutic from the reservoir to an interstitial space of the tumor in a therapeutically effective amount,
wherein, the chemotherapeutic reservoir includes a plurality of microspheres incorporating the anti-tumor chemotherapeutic and a suspending solution surrounding the microspheres.
34. The method of claim 33, wherein the chemotherapeutic reservoir comprises a mixture of the anti-tumor chemotherapeutic and a plasma protein in an amount effective to solubilize the anti-tumor chemotherapeutic.
35. The method of claim 34, wherein the plasma protein is selected from the group consisting of human serum albumin and -immunoglobulin.
36. The method of claim 34, wherein the microspheres comprise a biodegradable polymer.
37. The method of claim 36, wherein the biodegradable polymer is selected from the group consisting of polyacetic acid, polyglycolic acid and a co-polymer of polyglycolic and polyacetic acid.
38. The method of claim 34, wherein the microspheres comprise a non-biodegradable polymer.
39. The method of claim 38, wherein the non-biodegradable polymer is a ethylene-vinyl acetate copolymer.
40. The method of claim 34, wherein the anti-tumor agent is released from the microspheres in a therapeutically effective amount by degradation of the microspheres.
41. The method of claim 40, wherein about 50% of the anti-tumor chemotherapeutic from the microspheres within about 24 hours following delivery of the chemotherapeutic reservoir to the tumor.
42. The method of claim 40, wherein about 15 to about 25% of the anti-tumor chemotherapeutic from the microspheres within about 24 hours following delivery of the chemotherapeutic reservoir to the tumor.
43. The method of claim 34, wherein the anti-tumor chemotherapeutic is released from the microsphere by diffusion.
44. The method of claim 43, wherein the anti-tumor chemotherapeutic is continuously released from the microspheres in a therapeutically effective amount for a time period lasting from between about one week to about six months.
45. The method of claim 43, wherein the anti-tumor chemotherapeutic is continuously released from the microspheres in a therapeutically effective amount for a time period lasting from between about three weeks to about two months.
46. The method of claim 34, wherein the longest diameter of the microspheres are less than about 20 microns.
47. The method of claim 34, wherein the microspheres are microcapsules.
48. The method of claim 34, wherein the anti-tumor chemotherapeutic is an apoptosis inducing chemotherapeutic.
49. The method of claim 48, wherein the apoptosis inducing chemotherapeutic is selected from the group consisting of cisplatin, adriamycin, butyric acid, cyclophosphamide, etoposide, amsacrine, genistein, and mitoguazone.
50. The method of claim 48, wherein the anti-tumor chemotherapeutic is paclitaxel.
51. The composition of claim 50, wherein the paclitaxel is at a concentration from about 0.1 to about 10 mgmL.
52. The method of claim 50, wherein the paclitaxel is at a concentration from about 0.5 to about 5 mgmL.
53. The method of claim 34, wherein the suspending solution also includes an apoptosis inducing chemotherapeutic.
54. The method of claim 53, wherein the apoptosis inducing chemotherapeutic is paclitaxel.
55. The method of claim 53, wherein the total paclitaxel in both the microspheres and in the solution is about 70 to about 280 mg.
56. The method of claim 53, wherein the total paclitaxel in both the microspheres and in the solution is at a concentration of about 135 mgm2 to about 175 mgm2.
57. The method of claim 53, wherein between about 10% to about 90% of the paclitaxel is present in the microspheres.
58. The method of claim 53, wherein between about 60% to about 90% of the paclitaxel is present in the microspheres.
59. The method of claim 53, wherein between about 80% to about 90% of the paclitaxel is present in the microspheres.
60. The method of claim 34, further comprising a second anti-tumor chemotherapeutic in the suspending solution.
61. The method of claim 60, wherein the second anti-tumor chemotherapeutic is an apoptosis inducing chemotherapeutic.
62. The method of claim 60, wherein the second anti-tumor chemotherapeutic is selected from the group consisting of paclitaxel, cisplatin, adriamycin, butyric acid, cyclophosphamide, etoposide, amsacrine, genistein, and mitoguazone.
63. The method of claim 34, wherein the delivering step includes the step of positioning the chemotherapeutic reservoir within the tumor.
64. The method of claim 34, wherein the delivering step includes the step of intratumorally injecting the chemotherapeutic reservoir within the tumor.
65. The method of claim 34, wherein the delivering step includes the step of positioning chemotherapeutic reservoir adjacent to the tumor.

1. A flame retardant polyamide resin composition, comprising:
(a) about 30 to about 90 weight percent of a polyamide component comprising about 20 to 100 weight percent of at least one semiaromatic polyamide;
(b) at least one flame retardant comprising one or more of a phosphinate of the formula (I); a disphosphinate of the formula (II); and polymers of (I) andor (II)
wherein R1 and R2 are identical or different and are C1-C6 alkyl, linear or branched, andor aryl; R3 is C1-C10-alkylene, linear or branched, C6-C10-arylene, -alkylarylene or -arylalkylene; M is calcium ions, magnesium ions, aluminum ions andor zinc ions; m is 2 to 3; n is 1 or 3; and x is 1 or 2;

(c) zinc stannate; and
(d) 0 to about 60 weight percent of at least one inorganic reinforcing agent andor filler,
wherein the weight percentages of (a) and (d) are based on the total weight of the composition; wherein flame retardant (b) is present in an amount that is about 10 to about 45 percent of the weight of polyamide (a); and wherein zinc stannate (c) is present in an amount that is about 1 to about 50 percent of the weight of flame retardant (b).
2. The composition of claim 1, wherein the zinc stannate (c) is present in an amount that is about 1.5 to about 40 percent of the weight of flame retardant (b).
3. The composition of claim 1, wherein the flame retardant is aluminum diethylphosphinate andor aluminum methylethylphosphinate.
4. The composition of claim 1, wherein the semiaromatic polyamide is one or more selected from the group consisting of poly(dodecamethylene terephthalamide) (polyamide 12,T), poly(decamethylene terephthalamide) (polyamide 10,T), poly(nonamethylene terephthalamide) (polyamide 9,T), hexamethylene adipamidehexamethylene terephthalamide copolyamide (polyarmide 6,T6,6), hexamethylene terephthalamide2-methylpentamethylene terephthalamide copolyamide (polyamide 6,TD,T); hexamethylene adipamidehexamethylene terephthalamidehexamethylene isophthalamide copolyamide (polyamide 6,66,T6,I); and poly(caprolactam-hexamethylene terephthalamide) (polyamide 66,T).
5. The composition of claim 1, wherein the at least one inorganic reinforcing agent andor filler is present in about 5 to about 60 weight percent.
6. The composition of claim 7, wherein the inorganic reinforcing agent is glass fibers.
7. An article comprising the composition of claim 1.
8. A method for molding a flame retardant semiaromatic polyamide resin composition, comprising
providing a blended flame retardant semiaromatic polyamide resin composition comprising
(a) a 30 to about 90 weight percent of a polyamide component comprising about 20 to 100 weight percent of at least one semiaromatic polyamide;
(b) at least one flame retardant comprising one or more of a phosphinate of the formula (I); a disphosphinate of the formula (II); and polymers of (I) andor (II)
wherein R1 and R2 are identical or different and are C1-C6 alkyl, linear or branched, andor aryl; R3 is C1-C10-alkylene, linear or branched, C6-C10-arylene, -alkylarylene or -arylalkylene; M is calcium ions, magnesium ions, aluminum ions andor zinc ions; m is 2 to 3; n is 1 or 3; and x is 1 or 2;

(c) zinc stannate; and
(d) 0 to about 60 weight percent of at least one inorganic reinforcing agent andor filler,

wherein the weight percentages of (a) and (d) are based on the total weight of the composition; wherein flame retardant (b) is present in an amount that is about 10 to about 45 percent of the weight of polyamide (a); and wherein zinc stannate (c) is present in an amount that is about 1 to about 50 percent of the weight of flame retardant (b); and
melting and injecting said polyamide resin composition in a molding machine; at a temperature sufficient to provide a flowable melt;

wherein the injecting of the resin composition comprising components (a), (b), (c) and optionally (d) provides at least 50% less corrosion of a check ring than that of injecting a resin composition comprising components (a) (b) and optionally (d); as measured in a Mold Corrosion Test using a molding machine having a nozzle head with said check ring.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An apparatus for decoding an enhanced stereo sound effect from a stereo signal, comprising:
(a) an input for receiving a stereo signal including localisation cues, said stereo signal comprising a left channel and a right channel, each of said left and right channels being carried over a pair of wires including a positive lead and a negative lead;
(b) means for outputting said positive leads of said right and left channels directly; and
(c) means for outputting said negative leads of said right and left channels, said means for outputting including a decoding circuit for decoding the localisation cues from said stereo signal.
2. An apparatus according to claim 1, wherein said decoding circuit is a LR circuit.
3. An apparatus according to claim 1, wherein said decoding circuit is comprised of a resistor, a low-pass filter and a high-pass filter, connected in parallel.
4. An apparatus according to claim 3, wherein said cut-off frequency of said low-pass filter is 100 Hz, and said cut-off frequency of said high-pass filter is 10 kHz.
5. An apparatus for decoding an enhanced stereo sound effect from a stereo signal, comprising:
(a) an input for receiving a stereo signal, said stereo signal including fundamentals and localisation cues;
(b) means for generating a differential signal from said stereo signal;
(c) means for generating a differentiated signal from said stereo signal;
(d) means for introducing said differential signal into said differentiated signal to create a combined signal;
(e) means for introducing said fundamentals into said combined signal to create a decoded signal; and
(f) means for outputting said decoded signal.
6. An apparatus according to claim 5, wherein said stereo signal is comprised of a left and a right channel, each channel being carried on a positive and a negative wire, and wherein said means for generating a differential signal, said means for generating a differentiated signal, said means for introducing said differential signal and said means for introducing said fundamentals include connecting said negative wires of said right and left channels together, and connecting in parallel therein a resistor and a coil.
7. A method for decoding an enhanced stereo sound effect from a stereo signal, comprising:
(a) receiving a stereo signal, said stereo signal including fundamentals and localisation cues;
(b) generating a differential signal from said stereo signal;
(c) generating a differentiated signal from said stereo signal;
(d) introducing said differential signal into said differentiated signal to create a combined signal;
(e) introducing said fundamentals into said combined signal to create a decoded signal; and
(f) outputting said decoded signal into a left channel and a right channel.